ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2018
Cross-species evidence from human and rat brain transcriptome for growth factor signaling pathway dysregulation in major depression.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Transcriptomic Studies of Antidepressant Action in Rodent Models of Depression: A First Meta-Analysis.International journal of molecular sciences · 2022Pooled it
- Dihydromyricetin Modulates Neuropathic Pain and Depression: A Correlation with Hippocampal Vascular Endothelial Growth Factor in Mice.Journal of inflammation research · 2026Article
- The Art of Nanoimmunobiotechnomedicine in Depression Management.Advanced pharmaceutical bulletin · 2025Review
- Human umbilical cord mesenchymal stem cells reverse depression in rats induced by chronic unpredictable mild stress combined with lipopolysaccharide.CNS neuroscience & therapeutics · 2024Article
- Integrating Metabolomics and Network Pharmacology to Explore the Mechanism of Xiao-Yao-San in the Treatment of Inflammatory Response in CUMS Mice.Pharmaceuticals (Basel, Switzerland) · 2023Article
- New insights into effects of Kaixin Powder on depression via lipid metabolism related adiponectin signaling pathway.Chinese herbal medicines · 2023Article
- Current State of Modeling Human Psychiatric Disorders Using Zebrafish.International journal of molecular sciences · 2023Review
- Highly ExpressingJournal of immunology research · 2022Article
- The effect and mechanism of Jiao-tai-wan in the treatment of diabetes mellitus with depression based on network pharmacology and experimental analysis.Molecular medicine (Cambridge, Mass.) · 2021Article
- Molecular Mechanisms Associated with Antidepressant Treatment on Major Depression.Complex psychiatry · 2021Review
- Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response.Translational psychiatry · 2021Article
- MOUSSE: Multi-Omics Using Subject-Specific SignaturEs.Cancers · 2021Article
- Comparative Proteomic Characterization of Ventral Hippocampus in Susceptible and Resilient Rats Subjected to Chronic Unpredictable Stress.Frontiers in neuroscience · 2021Article
- Identification of the significant pathways of Banxia Houpu decoction in the treatment of depression based on network pharmacology.PloS one · 2020Article
- Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine.Pharmacology, biochemistry, and behavior · 2020Review
- Gene-level genome-wide association analysis of suicide attempt, a preliminary study in a psychiatric Mexican population.Molecular genetics & genomic medicine · 2019Article
- Protective effects of leptin against cerebral ischemia/reperfusion injury.Experimental and therapeutic medicine · 2019Review
- Fibroblast Growth Factors in Depression.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 5 countries.
Funding
Abstract
An enhanced understanding of the pathophysiology of depression would facilitate the discovery of new efficacious medications. To this end, we examined hippocampal transcriptional changes in rat models of disease and in humans to identify common disease signatures by using a new algorithm for signature-based clustering of expression profiles. The tool identified a transcriptomic signature comprising 70 probesets able to discriminate depression models from controls in both Flinders Sensitive Line and Learned Helplessness animals. To identify disease-relevant pathways, we constructed an expanded protein network based on signature gene products and performed functional annotation analysis. We applied the same workflow to transcriptomic profiles of depressed patients. Remarkably, a 171-probesets transcriptional signature which discriminated depressed from healthy subjects was identified. Rat and human signatures shared the SCARA5 gene, while the respective networks derived from protein-based significant interactions with signature genes contained 25 overlapping genes. The comparison between the most enriched pathways in the rat and human signature networks identified a highly significant overlap (p-value: 3.85 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.